CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

Published 2015 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
Authors
Keywords
-
Journal
NEUROLOGY
Volume 86, Issue 4, Pages 375-381
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2015-12-31
DOI
10.1212/wnl.0000000000002314

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.